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Abstract Endoplasmic reticulum (ER) stress leads to
activation of the unfolded protein response (UPR) signaling
cascade and induction of an apoptotic cell death, autop-
hagy, oncogenesis, metastasis, and/or resistance to cancer
therapies. Mechanisms underlying regulation of ER trans-
membrane proteins PERK, IRE1a, and ATF6a/b, and how
the balance of these activities determines outcome of the
activated UPR, remain largely unclear. Here, we report a
novel molecule transmembrane protein 33 (TMEM33) and
its actions in UPR signaling. Immunoblotting and northern
blot hybridization assays were used to determine the effects
of ER stress on TMEM33 expression levels in various cell
lines. Transient transfections, immunofluorescence, sub-
cellular fractionation, immunoprecipitation, and
immunoblotting were used to study the subcellular local-
ization of TMEM33, the binding partners of TMEM33, and
the expression of downstream effectors of PERK and
IRE1a. Our data demonstrate that TMEM33 is a unique ER
stress-inducible and ER transmembrane molecule, and a
new binding partner of PERK. Exogenous expression of
TMEM33 led to increased expression of p-eIF2a and
p-IRE1a and their known downstream effectors, ATF4-
CHOP and XBP1-S, respectively, in breast cancer cells.
TMEM33 overexpression also correlated with increased
expression of apoptotic signals including cleaved caspase-7
and cleaved PARP, and an autophagosome protein LC3II,
and reduced expression of the autophagy marker p62.
TMEM33 is a novel regulator of the PERK-eIE2a-ATF4
and IRE1-XBP1 axes of the UPR signaling. Therefore,
TMEM33 may function as a determinant of the ER stress-
responsive events in cancer cells.
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Abbreviations
ATF4 Activating transcription factor 4
ATF6 Activating transcription factor 6
ATF6f/c Cytosolic domain of ATF6
CHOP C/EBP(CCAAT/enhancer-binding protein)
homologous protein





IRE1a Inositol-requiring enzyme 1a
LC3II Microtubule-associated protein 1 light chain
3
PERK Protein kinase RNA-like ER kinase
TG Thapsigargin
TMEM33 Transmembrane protein 33
TN Tunicamycin
UPR Unfolded protein response
XBP1 X-box binding protein 1
XBP1-S Active (spliced) XBP1
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Introduction
The endoplasmic reticulum (ER) is involved in several
fundamental cellular processes including synthesis and
sorting of secretory and membrane proteins, detoxification,
and intracellular calcium homeostasis [1]. Correct folding of
proteins in the ER lumen is regulated by folding and oxi-
dizing enzymes in the presence of chaperones and glyco-
sylating enzymes dependent on ATP and high Ca2? levels.
Misfolded proteins are exported to the cytoplasm for pro-
teosomal degradation by a process known as the ER-asso-
ciated degradation (ERAD) [2]. ER stress, as defined by the
accumulation of misfolded or unfolded proteins above the
threshold levels in the ER lumen, leads to activation of an
ER-to-nucleus unfolded protein response (UPR) signaling
cascade. The ER transmembrane proteins protein kinase
RNA-like ER kinase (PERK), inositol-requiring enzyme 1a
(IRE1a) and activating transcription factor 6 (ATF6a/b)
sense ER stress, each then regulating one of the three distinct
axes of the UPR signaling cascade [3]. ER stress-activated
PERK phosphorylates serine 51 of eukaryotic translation
initiation factor 2a (eIF2a), followed by the suppression of
protein synthesis and a selective increase in ATF4 activity.
Downstream effectors of PERK signaling include both pro-
survival factors such as the transcription factor NRF2 and
microRNA miR-211, which are associated with adaptation
response, and pro-apoptotic factors including CHOP that can
induce cell death [4, 5]. Stress-induced phosphorylation and
activation of IRE1a results in activation of the transcription
factor X-box binding protein 1 (XBP1) and increased
expression of ER chaperones such as GRP78/BiP which, in
turn, increase protein folding capacity in the ER lumen.
Activated IRE1a also reduces protein load in the ER lumen
by cleaving mRNAs encoding secretory and membrane
proteins through regulated IRE1a-dependent decay (RIDD).
In the ATF6a/b arm of the UPR signaling, ATF6a/b is
transported to the golgi where it undergoes cleavage;
cleaved ATF6 (ATF6f/ATF6c) functions as a transcription
factor for several ER chaperones.
Mechanisms underlying regulation of PERK, IRE1a,
and ATF6a/b, and how the balance of these activities
determine outcome of the activated UPR, remain largely
unclear. Indeed, depending on the acute or chronic ER
stress and cellular context, activation of the UPR may lead
to apoptotic cell death, senescence, autophagy, oncogene-
sis, metastasis, and/or resistance to chemotherapeutics and
endocrines [6–14]. Identification of new molecules regu-
lating UPR signals may advance understanding of the
mechanistic and functional significance of UPR in cancer
biology and therapy.
Here, we report characterization of transmembrane
protein 33, TMEM33 (also known as SHINC-3) as a novel
ER stress-inducible and ER transmembrane molecule and
regulator of two main drivers of the UPR: PERK and
IRE1a. Our data show that TMEM33 is a new binding
partner of PERK. TMEM33 overexpression led to
increased expression levels of both p-eIF2a and p-IRE1a
and of their respective downstream effectors, ATF4 and
XBP1-S in breast cancer cells. TMEM33 overexpression
also led to increased expression of CHOP, cleaved caspase-
7, and the autophagosome marker LC3II in these cells.
Collectively, this work provides new mechanistic insights
into the regulation of PERK and IRE1a signaling pathways
via TMEM33 in cancer cells.
Materials and methods
Antibodies, reagents, and chemicals
Rabbit polyclonal antibody was custom generated against a
TMEM33-specific peptide, KKVLDARGSNSLPLLR
(amino acids 127–143; Covance Research Products Inc.,
Denver, PA). Polyclonal anti-GAPDH antibody (2275-PC-
1) was purchased from Trevigen (Gaithersburg, MD,
USA). Monoclonal anti-a-tubulin antibody (TU-02),
monoclonal anti-Myc antibody (9E10), monoclonal
horseradish peroxidase-conjugated anti-cMyc antibody
(9E10HRP), polyclonal anti-PERK antibody (H-300),
polyclonal anti-GRP78/BiP antibody (C-20), polyclonal
anti-IRE1 antibody (H-190), polyclonal anti-Calnexin
antibody (C-20), monoclonal anti-PARP antibody (F-2),
polyclonal anti-ATF4 antibody (H-290), polyclonal anti-
ATF-6a antibody (H-280), monoclonal anti-Cyclin D1
antibody (sc-20044); polyclonal anti-b-actin antibody (sc-
1616) and Protein A/G PLUS-Agarose immunoprecipita-
tion reagent were all purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Monoclonal anti-COX4
antibody (12C4) was obtained from Molecular Probes
(Carlsbad, CA, USA). Monoclonal anti-Myc antibody
(2276), monoclonal anti-PERK antibody (5683), poly-
clonal anti-phospho-eIF2a (Ser51) antibody (9721), poly-
clonal anti-eIF2a antibody (9722), monoclonal anti-
phospho-eIF2a antibody (3597), monoclonal anti-ATF4
antibody (11815), monoclonal anti-LC3II antibody
(12741), monoclonal anti-CHOP antibody (2895), poly-
clonal anti-cleaved-caspase-7 antibody (9491), polyclonal
anti-caspase-7 antibody, and polyclonal anti-cleaved PARP
antibody were all purchased from Cell Signaling Tech-
nology, Inc. (Beverly, MA, USA). Additional antibodies
and reagents used were as follows: monoclonal anti-ATF6
antibody (IMG-273, Imagnex); polyclonal anti-XBP1
antibody (GWB-BACB31, Genway); polyclonal anti-
phospho-IRE1a antibody (PA1-16927, Thermoscientific);
monoclonal anti-p62 antibody (610832, BD-Bioscience);
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FITC-conjugated monoclonal anti-Calnexin antibody (BD
Transduction Laboratories); horseradish peroxidase-conju-
gated mouse and rabbit secondary antibodies (Amersham
Pharmacia Biotech, Piscataway, NJ, USA); Lipofectamine
2000, Lipofectamine LTX, and Lipofectin (Invitrogen Life
Technologies, Carlsbad, CA, USA); Fu Gene HD (Roche);
proteinase inhibitor cocktail tablets (Roche Diagnostics,
Indianapolis, IN, USA); ECL Plus Western blotting
detection system (Amersham Biosciences); Coomassie
protein assay reagent and Surfact-Amps NP-40 (Pierce
Biotechnology, Inc., Rockford, IL, USA); Tween 20 (Bio-
Rad Laboratories, Inc., Hercules,CA, USA); Re-Blot plus
mild antibody stripping solution (Chemicon International,
Inc., Temecula, CA, USA); Restore Western blot stripping
buffer (21059, ThermoScientific), and thapsigargin, tuni-
camycin from Streptomyces sp., dimethyl sulphoxide
Hybri-Max Sterile filtered (DMSO), and etoposide (Sigma-
Aldrich, St. Louis, MO, USA).
Cell lines and cultures
MCF-7 human breast cancer cells were obtained from the
American Type Culture Collection (Rockville, MD, USA)
and Tissue Culture Shared Resource of the Georgetown
Lombardi Comprehensive Cancer Center. HEK293T
human embryonic kidney cells were obtained from the
American Type Culture Collection (Rockville, MD, USA).
Human prostate cancer cells (PC-3 and DU-145), breast
cancer cells (MDA-MB231), HeLa, and COS-1 cells were
obtained from the Tissue Culture Shared Resource of the
Georgetown Lombardi Comprehensive Cancer Center. All
cell lines were grown as monolayers in Dulbecco’s Mod-
ified Eagle Medium (DMEM) (Invitrogen Life Technolo-
gies, Carlsbad, CA, USA) supplemented with 5 or 10 %
heat-inactivated fetal bovine serum. Endocrine-sensitive
(LCC1) and endocrine-resistant breast cancer cells (LCC9),
and antiestrogen-resistant MCF-7 cells (MCF7RR) were
obtained and established as reported earlier [15–17].
LCC1, LCC9, and MCF7RR cells were maintained in
IMEM without phenol red and supplemented with 5 %
charcoal-stripped calf serum (CCS). All cell cultures were
maintained at 37 C under 95 % relative humidity and
95 % O2:5 % CO2 atmosphere.
Construction of Myc-TMEM33 expression vector
TMEM33 cDNA (741 bp) was amplified by RT-PCR using
total mRNA from human testes (Ambion, Foster City, CA)
and cloned into the pCR2.1 vector (Invitrogen). N-terminal
Myc-tagged TMEM33 ORF (771 bp) was amplified by
PCR using TMEM33 in pCR2.1 as template. The forward
primer sequence containing the translation initiation codon,
the Myc epitope (underlined), and Bgl II primer (bold) was
50-GAGATCTGCCATGGAGCAGAAACTCATCTCTG
AAGAGGACCTGATGGCAGATACGACCCCGAAC-
30, and the reverse primer sequence containing the MulI
primer (bold) was 50-GACGCGTCTATGGAACTGTTG
GTGCC -30 as described earlier [18]. The PCR conditions
were as follows: 95 C for 4 min; 40 cycles of denaturation
at 94 C for 30 s; annealing at 65 C for 1 min; extension
at 72 C for 1 min; and a final extension at 72 C for
5 min. The amplified product was subjected to elec-
trophoresis in 1 % agarose gels and cloned into the pCR3.1
expression vector. TMEM33 cDNA sequence was verified
by automated DNA sequencing of both strands using
vector-based forward and reverse primers as detailed ear-
lier [18, 19].
Transient cDNA transfections
COS-1, HEK-293T, and PC-3 prostate cancer cells were
transiently transfected using Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA). HeLa cells were transiently transfected
using FuGene HD (Roche), and MCF-7 and MDA-MB231
breast cancer cells were transiently transfected using
Lipofectamine LTX (Invitrogen) as described in Supple-
mentary Materials and methods.
Immunofluorescence and immunostaining
COS-1 cells were grown overnight on coverslips placed in a
six well plate, one coverslip/well. Approximately, 3 9 104
cells were seeded/well. Next day, cells were transfected with
1 lg ofMyc-TMEM33 or empty vector using Lipofectamine
2000. Forty eight hours post-transfection, the medium was
removed and cells were immediately fixed in 3.7 %
paraformaldehyde, followed by immunofluorescence and
immunostaining using various antibodies as described in
Supplementary Materials and methods.
Subcellular fractionation
Approximately, 5 9 106 MCF-7 cells were seeded per
150 mm tissue culture dish. Next day, the cells were col-
lected by trypsinization and washed once with ice-cold
phosphate-buffered saline (PBS). The cytosolic, mito-
chondrial (heavy membrane), microsomal (light mem-
brane), and nuclear fractions were isolated as described in
Supplementary Materials and methods.
Immunoprecipitation and immunoblotting
The whole cell lysate (approximately 2 mg protein) was
incubated with 25 lL of agarose-conjugated anti-Myc
antibody on a rotator at 4 C overnight. The antibody-
conjugated agarose beads were washed 1x in cell lysis
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buffer and used for immunoblotting as reported earlier [20]
and detailed in Supplementary Materials and methods.
Thapsigargin and tunicamycin treatments
Stock solutions of thapsigargin (TG, 2 mM) and tuni-
camycin (TU, 2 mg/mL) were made in DMSO and stored
at -20 C. Cells from approximately 80 % confluent
monolayers were used. The culture medium was removed
and fresh DMEM containing 10 % FBS and the desired
final concentration of TG or TU was added to the cells and
incubation continued for various periods, followed by cell
lysis and Western blotting as described in Supplementary
Materials and methods.
Results
TMEM33 is a novel endoplasmic reticulum
transmembrane protein
We identified TMEM33 as a novel cDNA fragment
(191 bp) in a differentially displayed mRNA screen of
cancer cells treated with antisense raf oligonucleotide or
control mismatch oligonucleotide [GenBank accession
number AF403224]. Subsequent sequential homology
search of the human expressed sequence tag (EST) data-
base [21] led to identification of the full-length TMEM33
cDNA sequence (7717 bp) as shown in Fig. 1a. The
longest open reading frame of the full-length TMEM33
cDNA encodes a new 247 amino acids (aa) protein (ap-
proximately 28 kDa Mr) (Fig. 1b, Supplementary Fig. 1).
The TMEM33 amino acid sequence revealed three trans-
membrane helices (32–52 aa, 101–121 aa, and 156–176
aa), at least one phosphorylation site (T65) and two ubiq-
uitination sites (K148 and K221) [22–24] (Fig. 1b). Using
northern hybridization, four major TMEM33 transcripts
(7.7, 4.0, 2.5, and 1.5 kb) were detected in most normal
human tissues and cancer cell lines tested (Fig. 2).
Based on prediction of its likely subcellular localization,
the TMEM33 protein appeared to be localized to ER [25].
Subcellular localization of TMEM33 was demonstrated
using a combination of immunofluorescence and bio-
chemical fractionation analyses. COS-1 cells were tran-
siently transfected with either a Myc epitope-tagged
TMEM33 expression vector (Myc-TMEM33) or empty
vector. Immunofluorescence staining showed co-localiza-
tion of Myc-TMEM33 with Calnexin and ER-tracker but
not mito-tracker or WGA staining (Fig. 3a). Expression of
Myc-TMEM33 in COS-1 transfectants was verified by
immunoblotting (Fig. 3b).
Subcellular localization of the endogenous TMEM33
protein was examined by cell fractionation and
immunoblotting using a custom-generated rabbit poly-
clonal antibody against a TMEM33-specific epitope (aa
127–143). The anti-TMEM33 antibody recognized an
approximately 28 kDa protein in human prostate cancer
cells (PC-3 and DU-145); pre-immune serum had no
immune reactivity at the corresponding location (Supple-
mentary Fig. 2a). The anti-TMEM33 antibody was further
validated by sequential immunoblotting of cell lysates from
COS-1 Myc-TMEM33 transfectants with anti-Myc and
anti-TMEM33 antibodies. These two antibodies recognized
an overlapping band at *28 kDa in COS-1 transfectants
(Supplementary Fig. 2b). Using the custom-generated anti-
TMEM33 antibody, human endogenous TMEM33
(*28 kDa) was detected in several human cancer cell lines
including A549, Aspc-1, Colo-357, MDA-MB435, MCF-7,
and HeLa cells (data not shown). In the combined cell
fractionation and immunoblotting assay, Calnexin was
detected in both the heavy membrane pellet (HM) and the
ER-containing microsomal fractions (MS) of MCF-7 cells;
heavy membrane pellets contain mitochondrial, lysosomal,
and ER-resident proteins. Similar to Calnexin, endogenous
TMEM33 expression was seen in both the HM and MS
fractions of MCF-7 cells but not in the nuclear or cytosolic
fractions (Fig. 3c). Together with the predicted 2D topol-
ogy of TMEM33 [26, 27] (Fig. 3d) these data establish
TMEM33 as a novel ER transmembrane resident protein.
TMEM33 is an ER stress-inducible molecule
The ER localization of TMEM33 prompted us to ask whe-
ther TMEM33 expression is stimulated in response to
known inducers of ER stress including thapsigargin (TG), an
inhibitor of ER Ca2? ATPase, tunicamycin (TU), an inhi-
bitor of N-linked glycosylation, and low glucose. Expression
of TMEM33 was analyzed in HeLa cells exposed to TG, TU
or low glucose. TMEM33 protein expression was increased
in response to ER stress (Fig. 4a, b). Consistent with these
observations, a significant induction of the largest TMEM33
transcript (7.7 kb) was seen in HeLa cells treated with
thapsigargin (Fig. 4c). As expected, GRP78/BiP, a well-
known ER stress-inducible protein chaperone in the ER
lumen, was also induced in HeLa cells under similar con-
ditions (data not shown). In addition, ER stress-inducible
expression of TMEM33 and GRP78/BiP was also noted in
PC-3 prostate cancer cells (data not shown). Thus, TMEM33
is a new ER stress-inducible protein.
TMEM33 overexpression is associated
with enhanced stimulation of the ER stress-
responsive PERK/p-eIF2a/ATF4 signaling pathway
To determine whether TMEM33 is a component of the ER
stress-inducible UPR signaling pathway, we first looked for
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interaction(s) between TMEM33 and the ER membrane-
resident molecules PERK, IRE1a, and ATF6. HEK293T
cells were transiently transfected with the Myc-TMEM33
plasmid and treated with 1 lM TG for various times. Using
a reciprocal co-immunoprecipitation assay, our findings
show an ER stress-related interaction between TMEM33
and PERK (Fig. 5a). Myc-TMEM33 did not interact with
either IRE1a or ATF6 under similar conditions (data not
shown). Next, we examined the effects of TMEM33
overexpression on downstream effectors of activated
PERK (p-eIF2a; ATF4). As shown in Fig. 5b and c, and
Supplementary Fig. 3, overexpression of TMEM33 was
associated with enhanced basal and ER stress-induced
expression of p-eIF2a and ATF4 in Myc-TMEM33
Fig. 1 Schematic maps of TMEM33 cDNA, and predicted open
reading frame and amino acid sequence of TMEM33. a Maps of the
complete human TMEM33 (alias SHINC3) cDNA and overlapping
partial clones are shown. The gray box represents the coding region
and the black boxes represent the 50- and 30- untranslated regions of
the cDNA sequence. Italicized numbers represent the original lengths
of the overlapping clones in the GenBank database. The NCBI
BLAST program [43] was used to identify the overlapping sequences
and deduce the full-length sequence of TMEM33 cDNA. b Predicted
open reading frame (366–1109 bp) and amino acid sequence align-
ment of TMEM33 protein (247 aa). Locations of three transmembrane
helices (32–52 aa, 101–121 aa, and 156–176 aa, underlined), a
phosphorylation site (T65, red) and two ubiquitination sites (K148
and K221, blue) are shown
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transfectants, relative to empty vector control transfected
HEK293T cells. These data establish TMEM33 as a novel
binding partner of PERK and demonstrate that TMEM33
overexpression correlates with enhanced activation of the
ER stress-inducible PERK/p-eIF2a/ATF4 signaling.
TMEM33 overexpression and increased expression
of ER stress-induced cell death signals
We next determined the effects of TMEM33 overexpres-
sion on various cell death signals. HeLa cells were tran-
siently transfected with a Myc-TMEM33 or control vector
and exposed to TG (1 lM) for indicated times, followed by
immunoblotting of whole cell lysates with various anti-
bodies (Fig. 6). For quantification of relative levels of
cleaved caspase 9, cleaved caspase 7 and cleaved PARP in
Myc-TMEM33 transfectants versus control vector, expres-
sion levels were first normalized against a-Tubulin in
corresponding lanes. The fold D in relative expression level
in Myc-TMEM33 cells was calculated by dividing nor-
malized value in Myc-TMEM 33 transfectants by normal-
ized value in pCR3.1 transfectants in the corresponding
treatment group. Basal levels of cleaved caspase 9 were
found to be higher in Myc-TMEM33 transfected HeLa cells
relative to control vector transfectants (Myc-TMEM33
versus pCR3.1, Cl. Caspase 9, untreated (UT), 1.8 fold).
Increased expression levels of cleaved caspase 7 and
cleaved PARP were observed in Myc-TMEM33 transfec-
tant HeLa cells following TG treatment relative to control
vector transfectants (Myc-TMEM33 versus pCR3.1: Cl.
Caspase 7, TG (1 lM, 48 h), 5.0 fold; Cl. PARP, TG
(1 lM, 48 h), 3.0 fold). Increased expression levels of
cleaved Caspase 7 and cleaved PARP were also observed
following TG treatment of COS-1 cells transiently trans-
fected with Myc-TMEM33 versus control vector transfec-
tants (Supplementary Fig. 4a). In addition, Caspase 2
expression was found to be increased in Myc-TMEM33
transfectant COS-1 cells versus control transfectants
(Supplementary Fig. 4a). Interestingly, expression of
cleaved caspase 3 did not seem to change in these cells
(data not shown). Furthermore, constitutive expression of
cleaved caspase 7 was also seen in TMEM33-transfected
Fig. 2 Expression analyses of TMEM33 transcripts in normal human
tissues and human cancer cell lines. The mRNA blots (Clontech) were
sequentially probed with a radiolabeled TMEM33 cDNA probe,
followed by b-actin or GAPDH cDNA probe. S.M., smooth muscle;
PBL, peripheral blood lymphocytes; HL-60, promyelogenous
leukemia; K-562, chronic myelogenous leukemia; MOLT-4, lym-
phoblastic leukemia; BL-Raji, Burkitt’s lymphoma; SW480, colorec-
tal adenocarcinoma; A549, lung carcinoma; G361, melanoma; DU-
145, prostate cancer
cFig. 3 TMEM33 is an ER transmembrane resident protein. a Im-
munofluorescence analysis of ER localization of TMEM33 in COS-1
transfectants. After 48 h of transfection with Myc-TMEM33 cDNA
expression vector, COS-1 transfectants were fixed and immunostained
as described in ‘‘Materials and methods’’ section. For ER-tracker or
Mito-tracker staining, transfected cells were first incubated with these
dyes. Right subpanels: a DAPI; d anti- Calnexin antibody; g ER-
tracker; j Mito-tracker; m, WGA. Middle subpanels (b, e, h, k, n):
anti-Myc antibody. Left panels (c, f, i, l, o): merge of corresponding
right and middle panels. b Expression of Myc-TMEM33 protein in
transiently transfected COS-1 cells was confirmed by immunoblotting
with anti-Myc antibody. The blot was reprobed with anti-GAPDH
antibody. UT untransfected. c The subcellular localization of
endogenous TMEM33. MCF-7 cells were homogenized and fraction-
ated into nuclear, heavy membrane (HM), microsomal (MS), and
cytosolic fractions, followed by sequentially immunoblotting of the
cell fractions using anti-TMEM33, anti-Calnexin (ER membrane),
anti-PARP (nucleus), anti-COX4 (mitochondria), and anti-tubulin
(cytosol) antibodies. WCE, whole cell extract. d The ER membrane
structure of TMEM33. TOPO2, transmembrane protein display
software, was used to display 2D topology of TMEM33. ER lumen,
N-terminus 1–31 aa; 122–155 aa; ER membrane, 32–52 aa; 101–121
aa; 156–176 aa; Cytoplasm, 53–100 aa; 177–247 aa—C terminus;
Potential phosphorylation site (T65) (red) and two ubiquitination sites
(K148 and K221) (blue) are shown
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MCF-7 breast cancer cells but not in control pCR3.1-
transfected cells (Fig. 7, Supplementary Fig. 4b).
TMEM33 overexpression and constitutive activation
of the PERK-p-elF1a-ATF4 and IRE1a-XBP1 axes
of the UPR signaling and autophagy in breast cancer
cells
To address the consequences of TMEM33 overexpression
in human cancer cells, MCF-7 breast cancer cells were
transiently transfected with either the Myc-TMEM33 or
pCR3.1 vector, followed by immunoblotting of the cell
lysates with antibodies against various components of the
UPR signaling pathways. Figure 7 shows that exogenous
expression of TMEM33 was sufficient to increase basal
levels of p-eIF2a, ATF4, CHOP, cleaved caspase 7,
p-IRE1a, and XBP1-S but not cleaved ATF6. In addition,
cyclin D1 expression, a marker of cell cycle progression
and oncogenesis, was decreased in Myc-TMEM33 trans-
fectant MCF-7 cells. The latter observations seem to be
inconsistent with data showing high TMEM33 expression
in several tumor tissues including breast cancer (Supple-
mentary Fig. 5). Moreover, TMEM33 is reported to be
amplified in approximately 10 % of breast cancer patient
xenografts [28–30]. During autophagy, microtubule-asso-
ciated protein-1 light chain 3 (LC3I) is converted to its
membrane-bound form (LC3II). We have previously
reported that overexpression of XBP1 can regulate autop-
hagy through its control of BCL2 [31–33]. Increased
expression of LC3II and decreased expression of p62/se-
questosome 1 (SQSTM1), ubiquitin-binding protein and
promoter of apoptosis, was detected in Myc-TMEM33
transfected MCF-7 cells relative to controls (Fig. 7). Sim-
ilar observations were made in hormone refractory MDA-
Fig. 4 TMEM33 is an ER stress-inducible molecule. a HeLa cells
were treated with indicated doses of thapsigargin (TG) or tunicamycin
(TU) for various times, followed by immunoblotting with anti-
TMEM33 antibody. The blots were reprobed with anti-GAPDH
antibody. The expression levels of TMEM33 were quantified using
ImageQuant software (Molecular Dynamics), and normalized against
GAPDH in corresponding lanes. The fold open triangle indicates
TMEM33 level at various doses or time points relative to control lane.
Data shown are representative of two to three independent experi-
ments. b HeLa cells were grown in high glucose (25 mM) DMEM
containing 10 % FBS. The medium was switched to low glucose
(5.5 mM) DMEM containing 10 % FBS for the times indicated,
followed by sequential immunoblotting with anti-TMEM33 antibody
and anti-GAPDH antibody. Normalized expression levels of
TMEM33 were quantified as in panel a. Data shown are represen-
tative of two independent experiments. c Northern blot analysis of
TMEM33 mRNA in HeLa cells treated with thapsigargin as shown.
The blot was reprobed with radiolabeled GAPDH cDNA. The
normalized expression levels of 7.7 kb TMEM33 transcript at various
time points were quantified using ImageQuant software (Molecular
Dynamics)
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Fig. 5 TMEM33 is a binding partner of PERK and TMEM33
overexpression correlates with increased levels of basal and ER
stress- induced p-elF2a and ATF4 expression. a TMEM33 interacts
with PERK in the presence of ER stress. HEK293T cells were
transiently transfected with Myc-TMEM33 for 48 h at 37 C,
followed by treatment with 1 lM TG for the times indicated. The
whole cell lysates were subjected to immunoprecipitation using anti-
Myc antibody or anti-PERK antibody-conjugated Protein A/G and the
immunoprecipitates were analyzed by Western blotting as indicated.
Representative data from two independent experiments are shown. IP
immunoprecipitation; IB immunoblotting; WCE whole cell extracts.
UT untreated. b Increased basal and ER stress-induced expression of
p-eIF2a in Myc-TMEM33 transfected HEK293T cells. HEK293T
cells were transiently transfected with Myc-TMEM33 or pCR3.1
(empty vector) and incubated for 48 h at 37 C, followed by treatment
with 1 lM TG as indicated. Whole cell lysates were analyzed by
Western blotting with anti-p-eIF2a antibody. Blots were reprobed
with anti- eIF2a and anti-a-Tubulin antibodies (top panel). Cell
lysates were also probed with anti-Myc and anti-a-Tubulin antibodies
(bottom panel). For quantification of relative p-eIF2a levels in Myc-
TMEM transfectants versus control vector at various time points, first
total eIF2a levels were normalized against a-Tubulin in correspond-
ing lanes. Expression levels of p-eIF2a were then normalized against
a-Tubulin-normalized eIF2a levels in corresponding lanes. The fold
D in p-eIF2a level was calculated by dividing normalized p-eIF2a
level in Myc-TMEM transfectants by normalized p-eIF2a level in
pCR3.1 transfectants in the corresponding treatment group. Repre-
sentative data from three independent experiments are shown. UT,
untreated. c Increased expression of ATF4 in Myc-TMEM33 trans-
fected HEK293T cells. Whole cell extracts of empty vector (pCR3.1)
or Myc-TMEM33 transfected cells were prepared after thapsigargin
treatment (TG) as described in Materials and methods. Cell lysates
were sequentially immunoblotted with anti-ATF4 and anti-a-Tubulin
antibodies (top panel). Cell lysates were also probed with anti-Myc
and anti-a-Tubulin antibodies (bottom panel). For quantification of
relative ATF4 levels in Myc-TMEM33 transfectants versus control
vector at various time points, expression levels of ATF4 were
normalized against a-Tubulin in corresponding lanes. The fold D in
ATF4 level was calculated by dividing normalized ATF4 level in
Myc-TMEM33 transfectants by normalized ATF4 level in pCR3.1
transfectants in the corresponding treatment group. Representative
data from two independent experiments are shown. UT untreated
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MB-231 breast cancer cells (Supplementary Fig. 6).
Hence, TMEM33 overexpression is associated with con-
stitutive activation of PERK-p-elF1a-ATF4 and IRE1a-
XBP1-S signaling and autophagy in breast cancer cells.
Discussion
This study is the first report of TMEM33 as a new ER
stress-inducible and ER transmembrane resident molecule.
PERK and IRE1a axes of the UPR play prominent roles in
regulation of adaptation and cell death signals, yet how
these two receptors are regulated remains unclear. Here, we
demonstrate: (1) TMEM33 is a novel binding partner of
PERK and that TMEM33 overexpression correlates with
increased expression of downstream effectors of PERK,
p-eIF2a, and ATF4, and cleaved caspase 7 in cells chal-
lenged with thapsigargin, (2) association of enhanced
expression of TMEM33 with increases in components of
the activated PERK and IRE1a signaling pathways
(p-eIF2a, ATF4, CHOP, cleaved caspase 7, XBP1-S) in
breast cancer cells, and (3) association of enhanced
Fig. 6 TMEM33 overexpression is associated with increased ER
stress-inducible expression of cleaved caspase 7 and cleaved PARP.
HeLa cells were transiently transfected withMyc-TMEM33 or pCR3.1
(empty vector) and incubated for 48 h at 37 C, followed by treatment
with 1 lM TG for indicated times. Cell lysates were analyzed by
western blotting for expression of pro-apoptotic signals. Blots were
reprobed with anti-a-Tubulin antibody (top panel). Cell lysates were
also probed with anti-Myc and anti-a-Tubulin antibodies (bottom
panel). UT untreated
Fig. 7 Exogenous expression
of TMEM33 in MCF-7 breast
cancer cells is associated with
constitutive activation of the
PERK and IRE1a axes of the
UPR signaling. MCF-7 cells
were transiently transfected
with Myc-TMEM33 or pCR3.1
control vector. Adherent and
floating cells were collected
24 h post-transfection. Cells
were lysed in RIPA lysis buffer
supplemented with protease
inhibitor (Roche), 10 mM
glycerophosphate, 1 mM
sodium orthovanadate, 5 mM
pyrophosphate, and 1 mM
PMSF. Cell lysates (10 lg
protein) were immunoblotted
with indicated antibodies (all
1:1000 dilution)
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expression of TMEM33 with increased autophagy in breast
cancer cells. Autophagy has been associated with tumor cell
resistance to various therapies. In pilot studies, we also tested
whether TMEM33 may serve as a new prognostic marker in
certain estrogen receptor-positive breast cancers. Gene
expression microarrays were used to measure TMEM33
expression in endocrine-resistant (LCC9, MCF7RR) and
sensitive breast cancer cells (LCC1 andMCF7) [15–17], and
in clinical specimens [34–37]. TMEM33 mRNA expression
was found to be higher in endocrine-resistant breast cancer
cells as compared with their matched sensitive control cells.
In addition, early recurrent breast cancer specimens showed
high TMEM33 expression when compared with non-recur-
rent breast tumors (Supplementary Fig. 7). Taken together,
our current observations suggest a working model where
TMEM33 may function as a critical determinant of the
balance between PERK and IRE1a-mediated apoptotic,
adaptive and neoplastic transformation events in cancer cells
(Fig. 8).
How TMEM33 expression is regulated remains
unknown. The proximal promoter region of the TMEM33
gene shows putative binding site for NRF-2, a prosurvival
transcription factor downstream of the activated PERK
(Supplementary Fig. 1c). It is tempting to speculate that an
as yet unknown combination of feedback and cross-talk
exists. For example, where ER stress activates PERK and
increases TMEM33 expression via NRF-2, and increased
TMEM33 overexpression, depending on the cell type,
promotes PERK and IRE-1a activated signaling. TMEM33
may also interact with other proteins. At least one phos-
phorylation site (Thr 65) and two ubiquitination sites (Lys
148 and Lys 221) are predicted within the open reading
frame of TMEM33 (Supplementary Fig. 1b). TMEM33
may be a member of the family of ubiquitin-modified
proteins [38–40]. The STRING database [41] also predicts
potential interaction of TMEM33 with ubiquitin C (UBC),
and ubiquitin specific peptidase 19 (USP19), associated
with ubiquitin-dependent proteolysis (Supplementary
Fig. 8). TMEM33 may also interact with the retention in
endoplasmic reticulum 1 protein (RER1), which is
involved in the retrieval of ER membrane proteins from the
early golgi compartment (Supplementary Fig. 8).
Present report supports the hypothesis that TMEM33
may function as a multi-faceted molecule in cancer cells.
While our data suggest that TMEM33 overexpression
correlates with enhanced expression of apoptotic signals
(CHOP and cleaved caspase7), constitutive expression of
TMEM33 was found to be high in a limited number of
endocrine-resistant breast cancer cells and in early recur-
rent breast cancer specimens tested. The latter observations
are consistent with the roles of PERK and ATF4 in tumor
cell survival [42]. Moreover, autophagy may increase
survival of tumor cells [8, 9]. We observed increased
expression of autophagosome marker LC3II and down-
regulation of p62/sequestosome 1 (SQSTM1) in breast
cancer cells overexpressing TMEM33, suggesting induc-
tion and completion of autophagy. In conclusion, TMEM33
offers a new regulatory mechanism of the UPR and may
serve as a determinant of the outcome of activated UPR
signaling cascade.
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